Metabolism of designer drugs of abuse: an updated review.
about
Impact of the emergence of designer drugs upon sports doping testingDevelopment of the first metabolite-based LC-MS(n) urine drug screening procedure-exemplified for antidepressants.Behavioral sensitization and cross-sensitization between methylphenidate amphetamine, and 3,4-methylenedioxymethamphetamine (MDMA) in female SD rats.Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept.Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse.Prevalence of legal and illegal stimulating agents in sports.Prevalence of new psychoactive substances: A retrospective study in hair.The in vivo and in vitro metabolism and the detectability in urine of 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MS(n.).Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MS(n) techniques.In vitro, in vivo and in silico metabolic profiling of α-pyrrolidinopentiothiophenone, a novel thiophene stimulant.Synthetic cathinones: a new public health problemIn vitro characterization of potential CYP- and UGT-derived metabolites of the psychoactive drug 25B-NBOMe using LC-high resolution MS.Identification of Metabolite Biomarkers of the Designer Hallucinogen 25I-NBOMe in Mouse Hepatic Microsomal Preparations and Human Urine Samples Associated with Clinical IntoxicationMephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMAIn vitro approaches to studying the metabolism of new psychoactive compounds.Cathinone derivatives: a review of their chemistry, pharmacology and toxicology.Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents.GHB and synthetic cathinones: clinical effects and potential consequences.Current applications of high-resolution mass spectrometry in drug metabolism studies.Synthetic cathinones (bath salts): legal status and patterns of abuse.2C or not 2C: phenethylamine designer drug review."Not for human consumption": a review of emerging designer drugs.Suspected impaired driving case involving α-pyrrolidinovalerophenone, methylone and ethylone.Recent developments in urinalysis of metabolites of new psychoactive substances using LC-MS.Screening for illicit drugs in pooled human urine and urinated soil samples and studies on the stability of urinary excretion products of cocaine, MDMA, and MDEA in wastewater by hyphenated mass spectrometry techniques.Novel Psychoactive Substances-Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs.Mephedrone ('bath salt') elicits conditioned place preference and dopamine-sensitive motor activation.Identification of designer drug 2C-E (4-ethyl-2, 5-dimethoxy-phenethylamine) in urine following a drug overdose.Strategies for ascertaining the interference of phase II metabolites co-eluting with parent compounds using LC-MS/MS.Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MSn, and LC-HR-MS/MS.Colorimetric detection and chromatographic analyses of designer drugs in biological materials: a comprehensive reviewOptimization, validation, and the application of liquid chromatography-tandem mass spectrometry for the analysis of new drugs of abuse in wastewaterToxicology of Specific Substances
P2860
Q28255977-1C5BF9F3-7A9A-453F-9001-2A74179C0D94Q30992027-FBC4970A-5DCF-42EA-9242-894B4CA9721CQ33678859-654C10D8-04C6-43F0-95FE-01ABDA31FADFQ33887048-9CCB118F-2F38-4BD1-AA5D-7FD90E139073Q34165511-8DE38834-12FF-4FC9-A745-50AB34B233C9Q34177175-55E7170D-63A6-440C-AFF5-765637152544Q34270004-40BB4145-4FD3-4C43-B0CE-5A2C5CC93204Q34377572-9C2B0510-8CB1-48F6-98E7-ADE9A9E70342Q34451894-564EDAE9-F0AD-40C6-8806-FD053DA9FC6EQ34504512-0C699B5B-DF89-4BE7-B86C-AC4C58B96254Q35710543-13F25F7F-3E8E-407A-98AA-49D0457210BCQ35779974-28C1DBF3-E410-46C1-B366-85217F91C5BDQ36062680-EE30C4DD-0D8C-4C70-A556-D699CB776D43Q36703786-408F0686-9E1F-4D5B-8209-C6884EF34D27Q37889234-8610FA34-CBE7-4F43-9654-66423846E9E6Q37900939-8D0656EA-DD54-4B46-B8A9-76214576FBFCQ37922114-96DD611E-E63A-4A7D-AF9D-4253687A05EDQ37940942-DA6A9D45-1C06-49FF-B18D-D3E1B02541FDQ37986333-A1FD05A7-051A-441B-81EC-21D8B2C6496BQ37990357-2305C82E-6079-45A3-97C3-E9D328FFB813Q38089682-86D25570-9968-4323-91F5-A6782F537D77Q38202898-F3D5F94A-716E-44F7-AFBB-D9D78F0EDD3EQ38248827-A9BF4EC1-D725-4DBA-BBD6-720EF40E402EQ38260819-22363820-DAFD-4FA8-8657-3643486262E6Q40903642-CF357354-5210-4EBE-982B-DDB54DCABCECQ41462770-C530A160-DA87-4384-99B9-0153F66AEE2BQ42409901-69C35099-EAF9-4714-818A-E722949E6EABQ42413569-FFD34413-FC22-4A21-B51E-20E0411A6F0FQ44996296-5FCFA804-B8D3-46C4-8154-B67E3DD7DA75Q53641072-24F28C2D-4E1F-41FB-9188-6A17F5411D0EQ56763257-91703019-76B9-4B23-B100-1E2D389995B1Q57523917-E8295BBA-081B-4E29-93A5-EA80814625C1Q57986556-572B006A-312A-4F44-8C60-4A61203917C4
P2860
Metabolism of designer drugs of abuse: an updated review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metabolism of designer drugs of abuse: an updated review.
@en
Metabolism of designer drugs of abuse: an updated review.
@nl
type
label
Metabolism of designer drugs of abuse: an updated review.
@en
Metabolism of designer drugs of abuse: an updated review.
@nl
prefLabel
Metabolism of designer drugs of abuse: an updated review.
@en
Metabolism of designer drugs of abuse: an updated review.
@nl
P1476
Metabolism of designer drugs of abuse: an updated review
@en
P2093
Markus R Meyer
P304
P356
10.2174/138920010791526042
P407
P577
2010-06-01T00:00:00Z